Progentos Therapeutics Overview
- Year Founded
-
2023
- Status
-
Private
- Employees
-
7
- Latest Deal Type
-
Series A
- Latest Deal Amount
-
$68.6M
- Investors
-
8
Progentos Therapeutics General Information
Description
Developer of a regenerative medicine platform designed to stimulate the body's own repair mechanisms to restore myelin in multiple sclerosis. The company offers novel small-molecule compounds that activate oligodendrocyte progenitor cells, enabling patients with chronic diseases, such as multiple sclerosis, to regain lost neurological function and improve their quality of life.
Contact Information
Website
www.progentos.comCorporate Office
- 763 Concord Avenue
- Cambridge, MA 02138
- United States
Corporate Office
- 763 Concord Avenue
- Cambridge, MA 02138
- United States
Progentos Therapeutics Valuation & Funding
| Deal Type | Date | Amount | Raised to Date | Post-Val | Status | Stage |
|---|---|---|---|---|---|---|
| 1. Early Stage VC (Series A) | 14-May-2024 | $68.6M | Completed | Pre-Clinical Trials |
Progentos Therapeutics Cap Table
| Stock | # of Shares Authorized |
Par Value | Dividend Rate (%) | Original Issue Price |
Liquidation | Liquidation Pref. Multiple |
Conversion Price | % Owned |
|---|---|---|---|---|---|---|---|---|
| Series A-4 | ||||||||
| Series A-3 | ||||||||
| Series A-2 | 16,250,000 | $0.000100 | 8% | $0.8 | $0.8 | 1x | $0.8 | 13.09% |
| Series A-1 | 5,602,736 | $0.000100 | 8% | $0.64 | $0.64 | 1x | $0.64 | 4.51% |
Progentos Therapeutics Comparisons
Industry
Financing
Details
Progentos Therapeutics Competitors (19)
One of Progentos Therapeutics’s 19 competitors is Rewind Therapeutics, a Venture Capital-Backed company based in Leuven, Belgium.
| Company Name | Financing Status | Location | Employees | Total Raised | Last Financing Date/Type | Last Financing Amount |
|---|---|---|---|---|---|---|
| Rewind Therapeutics | Venture Capital-Backed | Leuven, Belgium | ||||
| AnTolRx | Formerly VC-backed | Cambridge, MA | ||||
| Sudo Biosciences | Venture Capital-Backed | Carmel, IN | ||||
| Baliopharm | Venture Capital-Backed | Basel, Switzerland | ||||
| Prevail Therapeutics | Formerly VC-backed | New York, NY |
Progentos Therapeutics Patents
Progentos Therapeutics Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| JP-2026516101-A | Heterocyclic compounds and their uses | Pending | 09-May-2023 | ||
| AU-2024269869-A1 | Heterocyclic compounds and uses thereof | Pending | 09-May-2023 | ||
| EP-4709725-A1 | Heterocyclic compounds and uses thereof | Pending | 09-May-2023 | ||
| WO-2024233642-A1 | Heterocyclic compounds and uses thereof | Inactive | 09-May-2023 | ||
| AU-2022379973-A1 | Platelet-derived growth factor receptor (pdgfr) alpha inhibitors and uses thereof | Pending | 08-Nov-2021 | C07D471/04 |
Progentos Therapeutics Signals
Progentos Therapeutics Investors (8)
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds |
|---|---|---|---|---|
| Alta Partners | Venture Capital | Minority | ||
| Dolby Family Ventures | Venture Capital | Minority | ||
| Forbion | Venture Capital | Minority | ||
| Longwood Fund Management | Venture Capital | Minority | ||
| Mission BioCapital | Venture Capital | Minority |
Progentos Therapeutics FAQs
-
When was Progentos Therapeutics founded?
Progentos Therapeutics was founded in 2023.
-
Where is Progentos Therapeutics headquartered?
Progentos Therapeutics is headquartered in Cambridge, MA.
-
What is the size of Progentos Therapeutics?
Progentos Therapeutics has 7 total employees.
-
What industry is Progentos Therapeutics in?
Progentos Therapeutics’s primary industry is Drug Discovery.
-
Is Progentos Therapeutics a private or public company?
Progentos Therapeutics is a Private company.
-
What is the current valuation of Progentos Therapeutics?
The current valuation of Progentos Therapeutics is .
-
What is Progentos Therapeutics’s current revenue?
The current revenue for Progentos Therapeutics is .
-
How much funding has Progentos Therapeutics raised over time?
Progentos Therapeutics has raised $68.6M.
-
Who are Progentos Therapeutics’s investors?
Alta Partners, Dolby Family Ventures, Forbion, Longwood Fund Management, and Mission BioCapital are 5 of 8 investors who have invested in Progentos Therapeutics.
-
Who are Progentos Therapeutics’s competitors?
Rewind Therapeutics, AnTolRx, Sudo Biosciences, Baliopharm, and Prevail Therapeutics are some of the 19 competitors of Progentos Therapeutics.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read more -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process